



Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





NeoTYPE® AML Prognostic Profile

Alternative Name

AML Prognostic Profile

Methodology

Molecular

Test Description

This test is performed by sequencing the entire coding regions of the genes listed. ASXL1, BCOR, BRAF, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KIT, KMT2A (MLL), KRAS, NPM1, NRAS, PDGFRA, PHF6, PML, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1 and ZRSR2. For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.

Note: FLT3 by PCR (via [FLT3 Mutation Analysis](#)) is available to be ordered, as Client-Bill only, in conjunction with the NeoTYPE AML Prognostic Profile. It is reported separately from the NeoTYPE Profile for the purpose of prompt therapy selection in patients with a *new* diagnosis of AML.

Clinical Significance

Molecular profiling with the NeoTYPE AML Prognostic Profile is appropriate for AML patients with intermediate-risk cytogenetic abnormalities, which is a heterogeneous group. This Profile can refine and improve risk stratification by confirming intermediate risk or reclassifying patients to more favorable or unfavorable risk categories. This change in risk classification may have therapeutic implications. For patients with therapy-related AML, AML that evolved from MDS, and AML with myelodysplasia, we recommend instead the NeoTYPE MDS/CMML Profile.

Specimen Requirements

- **Bone marrow (Preferred):** 2 mL in EDTA tube.
- **Peripheral blood:** 5 mL in EDTA tube.
- **FFPE tissue:** Paraffin block. Alternatively, send 1 H&E slide plus 10-14 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative is the recommended fixative. Do not use zinc or mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.

Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*

81450x1

Medicare MoIDX CPT Code(s)*

81450

New York Approved

Yes

Level of Service

Global

Turnaround Time

14 days

Medical Necessity Resource

[Medical Necessity for NeoTYPE Myeloid Profiles](#)

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phone: 239.768.0600/ Fax: 239.690.4237
neogenomics.com
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.
All other trademarks are the property of their respective owners
Rev. 051524